Inside the research

Perrigo Company plc

PRGO Research profile · latest available data

Price overview

$15.42

▲ +0.74 (+5.0%)

52w hi$21.03
52w lo$8.83
Vol4.27M
As of25 Sep 2026

The Verdict

Hold

Our score +0.15

Short+0.55
Medium+0.14
Long-0.61

computed 2026-09-27

Key fundamentals

Perrigo Company plc

Healthcare · Drug Manufacturers - Specialty & Generic

Market cap$2.13B
Enterprise value$5.22B
Forward P/E6.43x
EV / EBITDA8.47x
P / S (ttm)0.52x
Profit margin-41.9%
Return on equity-48.7%
Revenue growth-3.2%
Debt / equity138.18

Layer Breakdown

LayerRawContribution
Fundamental-0.13
Sector+0.08
Technical+0.10
Earnings+0.00
Sentiment+0.39

macro × 1.00 · 2026-09-27

Business overview

Perrigo Company plc provides over-the-counter health and wellness solutions in the United States, Europe, and internationally. The company operates through Consumer Self-Care Americas and Consumer Self-Care International segments. It offers upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and oral electrolyte beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers. The company also offers healthy lifestyle products, such as smoking cessation and well-being products; skin care products consisting of dermatological care, scar management, lice treatment, and other products for various skin conditions; women's health products comprising feminine hygiene and contraceptives; vitamins, minerals, and supplements; and other miscellaneous self-care products. It sells its products under the Compeed, Dr. Fresh, Firefly, Good Sense, Good Start, Mederma, Nasonex, Plackers, Prevacid24HR, REACH, Rembrandt, Steripod, Opill, Solpadeine, Coldrex, Physiomer, NiQuitin, ACO, ellaOne, and Compeed brands. The company also offers contract manufacturing services. It sells its products through retail drug, supermarket, and mass merchandise chains; e-commerce stores; wholesalers; pharmacies; drug and grocery retailers; and para-pharmacies. The company was formerly known as Perrigo Company and changed its name to Perrigo Company plc in December 2013. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.

Ireland · www.perrigo.com

Risk Metrics

Beta vs SPX0.87
Corr SPX0.29
Annual vol47.3%
Annual ret-17.0%
Sharpe-0.36
Max DD-68.6%

Window: 504 trading days (504 obs)

Material Events

DateEvent8-K
2026-08-05Earnings Release, Exhibitsread
2026-07-06Officer / Director Changeread
2026-06-30Officer / Director Change, Reg FD Disclosure…read
2026-06-08Officer / Director Change, Reg FD Disclosure…read
2026-05-06Earnings Release, Exhibitsread
2026-05-05Officer / Director Change, Shareholder Vote…read
2026-04-30Acquisition / Disposition, Reg FD Disclosure…read
2026-04-22Earnings Release, Reg FD Disclosure…read
2026-03-23Material Agreement, Material Obligation…read
2026-02-26Earnings Release, Exhibitsread
2025-11-05Earnings Release, Reg FD Disclosureread
2025-08-06Earnings Release, Exhibitsread

Flow & Concentration

Insider 180d net$0
Insider buys / sells0 / 0
Insider biasNeutral
13F holders8
Top-5 share95.9%
HHI3,106 (concentrated)

Top Holders

HolderValueShares
State Street Corp$88.66M8.53M
AQR Capital Management$35.26M3.48M
Millennium Management$30.99M2.98M
Capital Research / Capital World$16.20M1.56M
Fidelity / FMR LLC$4.09M394.03K
Citadel Advisors$4.07M391.78K
Bridgewater Associates$3.37M324.08K
T. Rowe Price Group$90.40K8.70M

As of 2026-06-30

SEC Filings

DateFormDoc
2026-08-058-Kview
2026-08-0510-Qview
2026-07-234view
2026-07-154view
2026-07-154view
2026-07-143view
2026-07-104view
2026-07-104view
2026-07-103view
2026-07-104view
2026-07-104view
2026-07-104view
2026-07-104view
2026-07-104view
2026-07-094view

The Long Run

FY 2014–2025 · 11 years

LineLatestCAGRTrend
Revenue$4.66B+19.7%
Gross profit$1.49B+0.3%
Operating income$151.90M-15.2%
Net income-$171.80M-30.9%
Cash from ops$405.50M-2.3%

Indices

S&P SmallCap 600

Recent Sessions

DateOpenHighLowCloseVol
Sep 25$14.81$15.69$14.22$15.424.27M
Sep 24$13.87$15.10$13.84$14.687.73M
Sep 23$14.22$14.46$13.76$13.841.46M
Sep 22$14.20$14.45$14.16$14.312.32M
Sep 21$14.00$14.22$13.61$14.131.71M

Understand the score. Research layers are inputs to a model, and the available data has limits.

Read the methodology →